Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide

Journal of Clinical Pharmacology

Volumn 37, Issue 2, 1997, Pages 101-107

  Benz, Joan ^a   Oshrain, Carl ^a   Henry, Dan ^b   Avery, Christine ^a   Chiang, Yann Tong ^c   Gatlin, Marjorie ^c  

^a Foothill Clinic ^*

^b Foothill Clinic   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; LISINOPRIL; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT PLANNING;

EID: 0030980604     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04767.x     Document Type: Article

References (16)

1. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-176.
2. Medical Research Working Party (UK). MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97-104.
3. WHO Memorandum. 1992 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Clin Exp Hypert 1992;7:689-693.
4. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease, part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
5. Boissel J-P, Collet J-P, Lion L, et al: A randomised comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. J Hypert 1995;13:1059-1067.
6. Tikkanen I, Omvik P, Jensen HE: Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypert 1995;13:1342-1351.
7. Morice A H, Brown MJ and Higenbottam T: Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol 1989;13:(Suppl 3):S59-S62.
8. Johnston CI: Angiotensin receptor antagonists: focus on losartan. Lancet 1995;346:1403-1407.
9. Kaufman MP, Coleridge HM, Coleridge JCG: Bradykinin stimulates efferent C fibres in the intrapulmonary airways of dogs. J Appl Physiol 1980;48:511-517.
10. Jammes Y: Tonic sensory pathways of the respiratory system. Eur Respir J 1988;1:176-183.
11. Regioli D, Barabe J: Pharmacology of bradykinin and related peptides. Pharmacol Rev 1980;32:1-46.
12. Cascieri M, Bull H, Munford R: Carboxyl terminal tripeptide hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by Captopril and MK422. Mol Pharmacol 1988;25:287-293.
13. Müller P, Cohen T, de Gasparo M, et al: Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994;47:231-245.
14. Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, et al: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharm Ther 1996;60:341-346.
15. Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou Stock P, et al: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension Efficacy and safety compared to placebo and enalapril. J Hypert 1996;14:1147-1151.
16. Hegner G, Faust G, Freytag F, Meilenbrock S, Sullivan J, Bodin F: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Pharmacol, in press.